

Limited utility of Mayo 2012 cardiac staging system for risk stratification of patients with advanced cardiac AL amyloidosis - analysis of a uniformly treated cohort of 1,275 patients

Authors

Jahanzaib Khwaja,¹ Sriram Ravichandran,^{1,2} Joshua Bomsztyk,² Oliver Cohen,² Darren Foard,² Ana Martinez-Naharro,² Lucia Venneri,² Marianna Fontana,² Philip N. Hawkins,² Julian Gillmore,² Helen J. Lachmann,² Shameem Mahmood,^{1,2} Carol Whelan,² Amy A. Kirkwood³ and Ashutosh Wechalekar^{1,2}

¹University College London Hospital; ²National Amyloid Center, Royal Free London Hospital and ³Cancer Research UK & UCL Cancer Trials Center, UCL Cancer Institute, University College London, London, UK

Correspondence:

J. KHWAJA - j.khwaja@nhs.net

<https://doi.org/10.3324/haematol.2023.284348>

Received: September 22, 2023.

Accepted: January 2, 2024.

Early view: January 11, 2024.

©2024 Ferrata Storti Foundation

Published under a CC BY-NC license 

Supplementary table 1. Sensitivity and specificity for Mayo Stage IV and European modification stage IIIb

Timepoint	Mayo IV	European IIIb
6 months		
Sensitivity	46.3%	38.9%
Specificity	78.3%	89.8%
1 year		
Sensitivity	41.6%	37.0%
Specificity	79.1%	92.0%
2 years		
Sensitivity	38.8%	31.9%
Specificity	80.0%	92.8%
5 years		
Sensitivity	35.5%	25.4%
Specificity	81.8%	93.3%